Anika Therapeutics Q3 net loss narrows 87% to $311,000; Q3 revenue rises 10% to $30.59 million

• Anika Therapeutics’ third-quarter 2026 net loss narrowed 87% year over year to $311,000.
• Revenue rose 10% year over year to $30.59 million, while Commercial Channel revenue climbed 17% to $13.99 million.
• The FDA deemed the Hyalofast premarket approval application not approvable, primarily based on submitted clinical data.
• A new 10-year Hyvisc distribution partnership with Boehringer Ingelheim includes $8 million in expected upfront and milestone payments.
• Full-year 2026 revenue growth guidance increased to 6%–10% from 5%–10%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anika Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611060705PRIMZONEFULLFEED9872016) on November 06, 2026, and is solely responsible for the information contained therein.